drugset / Trial / NCT03847974
Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003
NaSingle-groupOpen-labelTreatment
Summary
To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)
Timeline
- Start
- 2019-02-14
- Primary completion
- 2020-04-07
- Completion
- 2020-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lerodalcibep | Protein / enzyme biologic | 300 mg | Subcutaneous |